1
PharmacoEconomics & Outcomes News 631 - 25 Jun 2011 Adalimumab adds up in juvenile idiopathic arthritis Adalimumab appears to be cost effective for the treatment of juvenile idiopathic arthritis (JIA) in Canada, say researchers who presented their findings at the 12th Annual Congress of the European League Against Rheumatism held in London, England in May 2011. Taking the Canadian healthcare system and societal perspectives, the study modelled the costs and outcomes for children treated with adalimumab (versus no adalimumab) over a 7-year time horizon (from ages 11 through to 17 years) and over a lifetime. Modelling over 7 years, the researchers estimated that adalimumab would cost $Can58 392 and $46 199 per QALY from a Canadian healthcare and societal perspective, respectively. When a lifetime horizon was modelled * , these values improved to $24 931 and $18 872 respectively – "indicating that treatment benefits persist over a lifetime", say the researchers. The researchers also found that if the timeframe was adjusted to an 11-year period and considered children from the age of 7 years being followed to age 18 years, costs reduced to $41 104 per QALY when a healthcare perspective was used. Similar improvements in the cost effectiveness were also noted when the societal perspective was used. * this included the expected costs for joint replacement procedures required in adulthood Simpson KN, et al. A Markov Model of Long-Term Cost Effectiveness of Adalimumab in Juvenile Idiopathic Arthritis in Canada. 12th Annual Congress of the European League Against Rheumatism : abstr. THU0076, 25 May 2011. Available from: URL: http://www.eular.org 803055473 1 PharmacoEconomics & Outcomes News 25 Jun 2011 No. 631 1173-5503/10/0631-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved

Adalimumab adds up in juvenile idiopathic arthritis

Embed Size (px)

Citation preview

PharmacoEconomics & Outcomes News 631 - 25 Jun 2011

Adalimumab adds up in juvenileidiopathic arthritis

Adalimumab appears to be cost effective for thetreatment of juvenile idiopathic arthritis (JIA) in Canada,say researchers who presented their findings at the 12thAnnual Congress of the European League AgainstRheumatism held in London, England in May 2011.

Taking the Canadian healthcare system and societalperspectives, the study modelled the costs andoutcomes for children treated with adalimumab (versusno adalimumab) over a 7-year time horizon (from ages11 through to 17 years) and over a lifetime.

Modelling over 7 years, the researchers estimatedthat adalimumab would cost $Can58 392 and $46 199per QALY from a Canadian healthcare and societalperspective, respectively. When a lifetime horizon wasmodelled*, these values improved to $24 931 and$18 872 respectively – "indicating that treatmentbenefits persist over a lifetime", say the researchers.

The researchers also found that if the timeframe wasadjusted to an 11-year period and considered childrenfrom the age of 7 years being followed to age 18 years,costs reduced to $41 104 per QALY when a healthcareperspective was used. Similar improvements in the costeffectiveness were also noted when the societalperspective was used.* this included the expected costs for joint replacementprocedures required in adulthood

Simpson KN, et al. A Markov Model of Long-Term Cost Effectiveness ofAdalimumab in Juvenile Idiopathic Arthritis in Canada. 12th Annual Congress ofthe European League Against Rheumatism : abstr. THU0076, 25 May 2011.Available from: URL: http://www.eular.org 803055473

1

PharmacoEconomics & Outcomes News 25 Jun 2011 No. 6311173-5503/10/0631-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved